HUP0301336A3 - Inhibitors of copper-containing amine oxidases and their use for preparation of pharmaceutical compositions - Google Patents

Inhibitors of copper-containing amine oxidases and their use for preparation of pharmaceutical compositions

Info

Publication number
HUP0301336A3
HUP0301336A3 HU0301336A HUP0301336A HUP0301336A3 HU P0301336 A3 HUP0301336 A3 HU P0301336A3 HU 0301336 A HU0301336 A HU 0301336A HU P0301336 A HUP0301336 A HU P0301336A HU P0301336 A3 HUP0301336 A3 HU P0301336A3
Authority
HU
Hungary
Prior art keywords
inhibitors
copper
preparation
pharmaceutical compositions
containing amine
Prior art date
Application number
HU0301336A
Other languages
English (en)
Original Assignee
Biotie Therapies Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotie Therapies Corp filed Critical Biotie Therapies Corp
Publication of HUP0301336A2 publication Critical patent/HUP0301336A2/hu
Publication of HUP0301336A3 publication Critical patent/HUP0301336A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
HU0301336A 2000-07-05 2001-07-04 Inhibitors of copper-containing amine oxidases and their use for preparation of pharmaceutical compositions HUP0301336A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21634100P 2000-07-05 2000-07-05
PCT/FI2001/000638 WO2002002090A2 (en) 2000-07-05 2001-07-04 Inhibitors of copper-containing amine oxidases

Publications (2)

Publication Number Publication Date
HUP0301336A2 HUP0301336A2 (hu) 2003-08-28
HUP0301336A3 true HUP0301336A3 (en) 2005-04-28

Family

ID=22806663

Family Applications (2)

Application Number Title Priority Date Filing Date
HU0301625A HUP0301625A3 (en) 2000-07-05 2001-07-04 1,3,4-oxadiazine-compounds as inhibitors of copper-containing amine oxidases, process for their preparation and their use for preparation of pharmaceutical compositions
HU0301336A HUP0301336A3 (en) 2000-07-05 2001-07-04 Inhibitors of copper-containing amine oxidases and their use for preparation of pharmaceutical compositions

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HU0301625A HUP0301625A3 (en) 2000-07-05 2001-07-04 1,3,4-oxadiazine-compounds as inhibitors of copper-containing amine oxidases, process for their preparation and their use for preparation of pharmaceutical compositions

Country Status (14)

Country Link
US (2) US6624202B2 (hu)
EP (2) EP1313718A2 (hu)
JP (2) JP2004502682A (hu)
CN (2) CN1450997A (hu)
AU (3) AU8216301A (hu)
CA (2) CA2414799A1 (hu)
HU (2) HUP0301625A3 (hu)
IL (2) IL153766A0 (hu)
NO (2) NO20026283L (hu)
NZ (2) NZ523464A (hu)
PL (2) PL360374A1 (hu)
RU (2) RU2003103286A (hu)
WO (2) WO2002002541A2 (hu)
ZA (2) ZA200300063B (hu)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL360374A1 (en) 2000-07-05 2004-09-06 Biotie Therapies Corporation Inhibitors of copper-containing amine oxidases
US6982286B2 (en) 2001-07-12 2006-01-03 Biotie Therapies Corp. Carbocyclic hydrazino inhibitors of copper-containing amine oxidases
WO2004067521A1 (en) * 2003-01-27 2004-08-12 Astellas Pharma Inc. Thiazole derivatives and their use as vap-1 inhibitors
WO2004087138A1 (en) * 2003-03-31 2004-10-14 Sucampo Ag Method for treating vascular hyperpermeable disease
ES2335769T3 (es) * 2003-05-26 2010-04-05 Biotie Therapies Corp. Vap-1 cristalina y sus usos.
FI20031927A0 (fi) * 2003-12-31 2003-12-31 Faron Pharmaceuticals Oy Terapeuttisesti vaikuttavia aineita ja niiden käyttö
FI20040136A0 (fi) * 2004-01-30 2004-01-30 Faron Pharmaceuticals Oy Erityisesti diabeetikoille soveltuvia koostumuksia
ES2342409T3 (es) * 2004-01-30 2010-07-06 Biotie Therapies Oyj Composiciones utiles especialmente para el tratamiento o prevencion del sindrome metabolico.
US8119651B2 (en) 2004-01-30 2012-02-21 Biotie Therapies Corp. Compositions useful especially for treatment or prevention of metabolic syndrome
FI20040270A0 (fi) * 2004-02-20 2004-02-20 Biotie Therapies Oyj Kuparia sisältävien amiinioksidaasien imhibiittoreina käyttökelpoiset hydratsinoalkoholijohdannaiset
DE602005013793D1 (de) * 2004-07-27 2009-05-20 Astellas Pharma Inc Thiazolderivate mit vap-1-hemmender wirkung
EP1791835A2 (en) * 2004-09-09 2007-06-06 Astellas Pharma Inc. Thiazole derivatives having vap-1 inhibitory activity
JP4140630B2 (ja) * 2005-11-10 2008-08-27 Ｔｄｋ株式会社 磁気ヘッドアセンブリ及び磁気ヘッドアセンブリの製造方法
US20080058922A1 (en) * 2006-08-31 2008-03-06 Cardiac Pacemakers, Inc. Methods and devices employing vap-1 inhibitors
US8372399B2 (en) * 2006-08-31 2013-02-12 Cardiac Pacemakers, Inc. Bispecific antibodies and agents to enhance stem cell homing
US8636995B2 (en) * 2006-08-31 2014-01-28 Cardiac Pacemakers, Inc. Methods and devices to regulate stem cell homing
FI20061156A0 (fi) 2006-12-27 2006-12-27 Elina Kivi Uusia peptidejä
WO2009061830A1 (en) * 2007-11-06 2009-05-14 Massachusetts Eye & Ear Infirmary Methods and compositions for treating conditions associated with angiogenesis using a vascular adhesion protein-1 (vap-1) inhibitor
WO2009066152A2 (en) 2007-11-21 2009-05-28 Pharmaxis Ltd. Haloallylamine inhibitors of ssao/vap-1 and uses therefor
TWI437986B (zh) 2008-01-31 2014-05-21 R Tech Ueno Ltd 噻唑衍生物及使用該衍生物作為ｖａｐ－１抑制劑之用途
TWI490214B (zh) 2008-05-30 2015-07-01 艾德克 上野股份有限公司 苯或噻吩衍生物及該等作為ｖａｐ－１抑制劑之用途
US8906642B2 (en) 2008-09-03 2014-12-09 Universitat Autonoma De Barcelona Methods and compositions for the treatment and diagnosis of haemorrhagic conversion
RU2400233C1 (ru) 2009-07-07 2010-09-27 Общество с ограниченной ответственностью "Вирфарм" Способ лечения заболеваний печени различного генеза
UA112154C2 (uk) 2009-09-08 2016-08-10 Біоті Терапіс Корп. Застосування повністю людського анти-vap-1-антитіла для лікування фіброзних станів
EP2479165B1 (en) 2009-09-16 2017-10-25 Astellas Pharma Inc. Glycine compound
RU2010145439A (ru) 2010-11-08 2012-05-20 Виктор Вениаминович Тец (RU) Средство для лечения поражений печени, вызванных воздействием химических или биологических агентов
FI20115234A0 (fi) 2011-03-08 2011-03-08 Biotie Therapies Corp Uusia pyridatsinoni- ja pyridoniyhdisteitä
HUE028394T2 (hu) 2011-03-15 2016-12-28 Astellas Pharma Inc Guanidin vegyület
US20160113893A1 (en) 2013-06-12 2016-04-28 Proximagen Limited New therapeutic uses of enzyme inhibitors
ES2714125T3 (es) 2014-04-15 2019-05-27 Pecsi Tudomanyegyetem Inhibidores de la amino oxidasa sensible a la semicarbazida para uso como analgésicos en una neuropatía traumática y una inflamación neurogénica
WO2015189534A1 (en) 2014-06-12 2015-12-17 Proximagen Limited Vap-1 inhibitors for treating muscular dystrophy
RU2595868C1 (ru) 2015-03-27 2016-08-27 Виктор Вениаминович Тец Лекарственное средство с гепатопротекторной активностью
JP2018076236A (ja) 2015-06-05 2018-05-17 株式会社アールテック・ウエノ がんを処置するための医薬組成物
CA3007768A1 (en) 2015-12-07 2017-06-15 Benevolentai Cambridge Limited Vap-1 inhibitors for treating pain
CN109810041B (zh) * 2017-11-21 2023-08-15 药捷安康(南京)科技股份有限公司 卤代烯丙基胺类ssao/vap-1抑制剂及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3377345A (en) * 1966-09-23 1968-04-09 Dow Chemical Co Substituted 3, 4, 5, 6-tetrahydro-2h-1, 3, 4-oxadiazin-2-one compounds and method ofpreparation thereof
US3486916A (en) 1966-12-22 1969-12-30 William A Cordon Cement mixes and the production of articles therefrom
SE320311B (hu) 1968-07-15 1970-02-02 Mo Och Domsjoe Ab
AU4055593A (en) * 1992-05-15 1993-12-13 University Of Saskatchewan Method for preventing endothelium damage in mammals and for alleviating pain associated with gout and arthritis
US5413634A (en) 1993-08-06 1995-05-09 Arco Chemical Technology, L.P. Cement composition
CA2117585C (en) 1993-09-14 2001-06-05 Edward T. Shawl Cement composition
AU2696795A (en) 1994-08-25 1996-03-14 W.R. Grace & Co.-Conn. Shrinkage reduction cement composition
US5618344A (en) 1995-03-06 1997-04-08 W. R. Grace & Co.-Conn. Cement composition
US5556460A (en) 1995-09-18 1996-09-17 W.R. Grace & Co.-Conn. Drying shrinkage cement admixture
US5603760A (en) 1995-09-18 1997-02-18 W. R. Grace & Co.-Conn. Cement admixture capable of inhibiting drying shrinkage and method of using same
PL360374A1 (en) 2000-07-05 2004-09-06 Biotie Therapies Corporation Inhibitors of copper-containing amine oxidases

Also Published As

Publication number Publication date
NZ523463A (en) 2004-06-25
HUP0301625A2 (hu) 2003-11-28
PL360353A1 (en) 2004-09-06
PL360374A1 (en) 2004-09-06
EP1313718A2 (en) 2003-05-28
NO20026282D0 (no) 2002-12-30
HUP0301336A2 (hu) 2003-08-28
JP2004502682A (ja) 2004-01-29
EP1301495A2 (en) 2003-04-16
NO20026283D0 (no) 2002-12-30
WO2002002090A3 (en) 2002-05-16
WO2002002090A2 (en) 2002-01-10
JP2004501962A (ja) 2004-01-22
US6624202B2 (en) 2003-09-23
HUP0301625A3 (en) 2005-04-28
CA2414799A1 (en) 2002-01-10
US20040106654A1 (en) 2004-06-03
CA2414807A1 (en) 2002-01-10
US20020173521A1 (en) 2002-11-21
NZ523464A (en) 2003-10-31
AU2001282163B2 (en) 2004-12-09
AU2001282162A1 (en) 2002-01-14
NO20026282L (no) 2003-03-03
WO2002002541A3 (en) 2002-04-18
IL153766A0 (en) 2003-07-06
IL153767A0 (en) 2003-07-06
ZA200300064B (en) 2003-07-22
ZA200300063B (en) 2003-07-22
AU8216301A (en) 2002-01-14
CN1450998A (zh) 2003-10-22
RU2003103286A (ru) 2004-08-20
NO20026283L (no) 2003-02-28
WO2002002541A2 (en) 2002-01-10
CN1450997A (zh) 2003-10-22
RU2003103291A (ru) 2005-01-27

Similar Documents

Publication Publication Date Title
HUP0301336A3 (en) Inhibitors of copper-containing amine oxidases and their use for preparation of pharmaceutical compositions
HUP0401097A3 (en) Carbocyclic hydrazino inhibitors of copper-containing amine oxidases, process for their preparation and pharmaceutical compositions containing them
HUP0400206A3 (en) Imidazolidindion derivatives having metalloproteinase inhibitor effect a their use for preparation of pharmaceutical compositions and pharmaceutical compositions containing them
HUP0302485A3 (en) Arylmethylamine derivatives for use as tryptase inhibitors and pharmaceutical compositions containing them
HUP0401984A3 (en) Use of type 4 phosphodiesterase inhibitors for preparation of pharmaceutical compositions and combination with other active ingredients
HUP0300855A3 (en) Peptidmomimetic protease inhibitors, pharmaceutical compositions and their use
HUP0302412A3 (en) Betha-carboline derivatives useful as inhibitors of phosphodiesterase and pharmaceutical compositions containing the same
AU7392101A (en) 8-quinolinxanthine and 8-isoquinolinxanthine derivatives as pde 5 inhibitors
HK1091840A1 (en) Methods and compositions for therapeutic use of rna interference
HUP0301683A3 (en) Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral indopeptidase, their intermediates, process for their preparation, pharmaceutical compositions containing them and their use
AU9092501A (en) Compositions and methods for inhibition of hiv-1 infection
EP1252325A4 (en) COMPOSITIONS AND METHODS FOR INHIBITING HIV-1 INFECTION
HUP0204159A3 (en) Prostaglandin compositions and their use for preparation of pharmaceutical compositions for treatment male erectile dysfunction
AU2001244355A1 (en) Heterobiarylsulphonamides and their use as pde 7 inhibitors
HUP0302160A3 (en) Pharmaceutical compositions containing the combination of gaba agonists and sorbitol dehydrogenase inhibitors
AU5956001A (en) Novel compositions and methods for enhancing potency or reducing adverse side effects of opioid agonists
AU2002367903A8 (en) Biologic-chemical herbicide compositions and methods of use
SI1411921T1 (sl) Farmacevtski sestavki, ki vsebujejo terbinafin, in njihova uporaba
HUP0400654A3 (en) Substituted 8-arylquinoline phosphodiesterase 4 inhibitors and pharmaceutical compositions containing them
HUP0303731A3 (en) Sulfonylguanidines and their use for preparation of pharmaceutical compositions
IL153487A0 (en) Pharmaceutical compositions and methods for use
HUP0300860A3 (en) Pharmaceutical compositions suitable for treatment of urinary dysfunction
IL153897A0 (en) Pharmaceutical compositions and methods for use
HUP0301348A3 (en) Analgesic and anti-inflammatory compositions containing gox-2 inhibitors and their use
HUP0303341A3 (en) Inhibitor of monoamine uptake and pharmaceutical compositions containing it

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished